Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial

The Lancet

Volumn 371, Issue 9606, 2008, Pages 57-63

  Tyrer, Peter ^a   Oliver Africano, Patricia C ^a   Ahmed, Zed ^b   Bouras, Nick ^c   Cooray, Sherva ^d   Deb, Shoumitro ^e   Murphy, Declan ^c   Hare, Monica ^b   Meade, Michael ^a   Reece, Ben ^a   Kramo, Kofi ^a   Bhaumik, Sabyasachi ^f   Harley, David ^g   Regan, Adrienne ^h   Thomas, David ⁱ   Rao, Bharti ^a   North, Bernard ^a   Eliahoo, Joseph ^a   Karatela, Shamshad ^g   Soni, Anju ^j   Crawford, Mike ^a   more..

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f LEICESTERSHIRE PARTNERSHIP NHS TRUST   (United Kingdom)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h Orme Lodge   (United Kingdom)

ⁱ NORTH EAST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^j WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE;

ADULT; AGGRESSION; AGITATION; ARTICLE; AUSTRALIA; BEHAVIOR DISORDER; CAREGIVER BURDEN; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRESS SYNDROME; DRUG DOSE INCREASE; DRUG EFFECT; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEALTH CARE; HEALTH CARE COST; HUMAN; INTELLIGENCE QUOTIENT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 37449030577     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60072-0     Document Type: Article

References (29)

1. Smith S., Branford D., Collacott R., Cooper S.-A., and McGrother C. Prevalence and cluster typology of maladaptive behaviors in a geographically defined population of adults with learning disabilities. Br J Psychiatry 169 (1996) 219-227
2. Qureshi H., and Alborz A. Epidemiology of challenging behaviour. Ment Handicap Res 5 (1992) 130-145
3. McGrother C., Byrne V., Thorp C., Tyrer F., and Watson J. Leicestershire learning disability register: annual report for the Department of Health 2006 (2007), University of Leicester, Leicester
4. Cooper S.-A., Smiley E., Morrison J., Williamson A., and Allan L. Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. Br J Psychiatry 190 (2007) 27-35
5. Bair H., and Herold W. Efficacy of chlorpromazine in hyperactive mentally retarded children. Arch Neurol Psychiatry 74 (1955) 363-364
6. Branford D. A study of the prescribing for people with learning disabilities living in the community and in National Health Service care. J Intellect Disabil Res 38 (1994) 577-586
7. Corbett J. Psychiatric morbidity and mental retardation. In: James F., and Snaith R. (Eds). Psychiatric illness and mental handicap (1979), Gaskell, London 11-25
8. Linaker O. Frequency and determinants for psychotropic drug use in an institution for the mentally retarded. Br J Psychiatry 156 (1990) 525-530
9. Lund J. The prevalence of psychiatric disorder in mentally retarded adults. Acta Psychiat Scand 72 (1985) 563-570
10. Brylewski J., and Duggan L. Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomised controlled trials. Cochrane Database Syst Rev 3 (2007) CD000377.
11. Sorgi P., Ratey J., Knoedler D., Markert R., and Reichman M. Rating aggression in the clinical setting a retrospective adaptation of the Overt Aggression Scale: preliminary results. J Neuropsychiat 3 (1991) 552-556
12. Oliver P., Crawford M., Rao B., Reece B., and Tyrer P. Modified overt aggression scale (MOAS) for people with intellectual disability and aggressive challenging behaviour: a reliability study. J Appl Res Intellect Disabil 20 (2007) 368-372
13. Aman M., Singh N., Stewart A., and Field C. The aberrant behaviour checklist: a behaviour rating scale for the assessment of treatment effects. Am J Ment Defic 89 (1985) 485-491
14. Pruchno R. The effects of help patterns on the mental health of spouse caregivers. Res Aging 12 (1990) 57-71
15. Schalock R., and Keith K. Quality of life questionnaire (1993), IDS Publishing Corporation, Worthington
16. Lingjaerde O., Ahlfors U., Bech P., et al. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiat Scand 334 suppl (1987) 1-100
17. Guy W. ECDEU assessment manual for psychopharmacology (DHEW Public. No ADM-76-338) (1976), Government Printing Office, Washington DC 217-222
18. Prosser H., Moss S., Costello H., Simpson N., Patel P., and Rowe S. Reliability and validity of the Mini PAS-ADD for assessing psychiatric disorders in adults with intellectual disability. J Intellect Disabil Res 42 (1998) 264-272
19. Beecham J. Collecting and estimating costs. In: Knapp M. (Ed). The economic evaluation of mental health care (1995), Ashgate Publishing Ltd, London 61-82
20. Van den Borre R., Vermote R., Buttiens M., et al. Risperidone as an add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. Acta Psychiat Scand 87 (1993) 167-171
21. Gagiano C., Read S., Thorpe L., Eerdekens M., and Van Hove I. Short and long term efficacy and safety of risperidone in adults with disruptive behaviour disorders. Psychopharmacol 179 (2005) 629-636
22. Einfeld S. Systematic management approach to pharmacotherapy for people with learning disabilities. Adv Psychiat Treatment 7 (2001) 43-49
23. Robertson J., Emerson E., Gregory N., Hatton C., Kessissiglou S., and Hallam A. Receipt of psychotropic medication by people with intellectual disability in residential settings. J Intellect Disabil Res 44 (2000) 666-676
24. Ashcroft R., Fraser B., Kerr M., and Ahmed Z. Are antipsychotic drugs the right treatment for challenging behaviour in learning disability? The place of a randomised trial. J Med Ethics 27 (2001) 338-343
25. Xenitidis K., Henry J., Russell A., Ward A., and Murphy D. An inpatient treatment model for adults with mild intellectual disability and challenging behaviour. J Intellect Disabil Res 43 (1999) 128-134
26. Taylor J., Novaco R., Gillmer B., and Thorne I. Cognitive-behavioural treatment of anger intensity among offenders with intellectual disabilities. J Appl Res Intellect Disabil 15 (2002) 151-165
27. McCracken J., McGough J., Shah B., et al. Risperidone in children with autism and serious behavioural problems. N Engl J Med 347 (2002) 314-320
28. Haessler F., Glaser T., Beneke M., Pap A., Bodenschatz R., and Reis O. Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours: discontinuation study. Br J Psychiatry 190 (2007) 447-448
29. Alexander J., Tharyan P., Adams C., John T., Mol C., and Philip J. Rapid tranquilization of violent or agitated patients in a psychiatric emergency setting. Br J Psychiatry 185 (2004) 63-69